In a challenging market environment, shares of Savara Inc. (NASDAQ: ) hit a 52-week low, falling to $2.81. The pharmaceutical company, which specializes in rare respiratory diseases, has faced significant problems over the past year, which is reflected in a one-year change showing a decline of 32.7%. Despite these challenges, InvestingPro data shows that the company maintains strong liquidity with a current ratio of 17.7 and more cash than debt on its balance sheet. Investors have been wary as the company navigates the complex healthcare landscape and the stock price struggles to regain momentum. This latest price level marks a worrisome turning point for shareholders who are closely watching the company’s performance and potential recovery strategies. With analyst price targets ranging from $5 to $16, detailed analysis and additional insights are available through the comprehensive Pro Research Report, part of InvestingPro’s comprehensive coverage of more than 1,400 US stocks.
In other recent news, Savara Inc. faced a price target cut by HC Wainwright, lowering it from $10 to $6, amid concerns about the company’s ability to meet patient identification targets for Molbreevi. However, the company maintained its buy rating on the stock. In contrast, Evercore ISI downgraded the stock from Outperform to In Line and cut its price target to $5.00, citing production as the primary risk to the approval. Piper Sandler maintained an Overweight rating on Savara with a $16.00 price target, highlighting the potential of Savara’s MOLBREEVI as the first approved aPAP therapeutic.
Savara reported earnings per share of ($0.12), slightly below the ($0.10) Oppenheimer forecast and consensus estimates. Additionally, the company announced a $100 million equity offering of 26,246,720 shares managed by firms such as Jefferies, Piper Sandler and Guggenheim Securities.
On the company’s development front, Savara is on track for potential approval by the end of 2025 for MOLBREEVI in autoimmune pulmonary alveolar proteinosis (aPAP), assuming the treatment receives priority review. The company also launched an expanded access program for molgramostim, a potential aPAP drug, and named Braden Parker as its new chief commercial officer. These are among the recent achievements in Savara.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
